On May 4, 2023, Truist Securities analyst David Macdonald maintained a Buy rating on Amedisys (NASDAQ:AMED) while lowering the price target from $115 to $97. According to Fintel reports, the average one-year price target for Amedisys is $110.16, with forecasts ranging from a low of $84.84 to a high of $136.50. The average price target represents an increase of 38.01% from its latest reported closing price of $79.82.
Amedisys is a healthcare company that offers home health, hospice, and personal care services. In the last quarter, the company had revenue of $562.10 million, compared to analyst estimates of $560.46 million. Amedisys had a return on equity of 22.08% and a net margin of 7.68%. The business’s 50-day simple moving average is $79.99, and its 200-day simple moving average is $86.33. Amedisys has a 1-year low of $69.36 and a 1-year high of $131.32.
Previously, Truist Financial cut their target price on shares of Amedisys from $130.00 to $115.00 and set a “buy” rating for the company in a research note on Thursday, April 13th. However, StockNews.com raised Amedisys from a “hold” rating to a “buy” rating.
AMED Stock Performance and Forecast for the Next Five Years
On May 4, 2023, AMED stock opened at $76.56, down 2.59% from the previous day’s close of $78.59. The day’s range was between $73.54 and $78.66, with a volume of 197,581 shares traded. The average volume over the last three months was 424,670.
AMED’s market capitalization was $2.6 billion, with a price-to-earnings (P/E) ratio of 20.6 and a price-to-sales ratio of 1.23. The price-to-book ratio was 2.48.
The earnings growth for AMED was negative in the last year and this year, with a decline of 43.05% and 14.75%, respectively. However, the company’s earnings growth for the next five years is expected to be positive at 2.42%. The revenue growth for the last year was modest at 0.41%.
AMED belonged to the Health Services sector and the Medical/Nursing Services industry. The company had no executives to display, and its corporate headquarters were located in Baton Rouge, Louisiana.
The next reporting date for AMED was on August 1, 2023, with an EPS forecast of $1.12. The company’s annual revenue for the last year was $2.2 billion, with an annual profit of $118.6 million. The net profit margin was 5.34%.
In conclusion, AMED stock had a lackluster performance on May 4, 2023, with a decline in its opening price and lower-than-average trading activity. However, the company’s positive earnings growth forecast for the next five years could be a potential upside for the stock. Investors should keep an eye on the company’s upcoming earnings report on August 1, 2023, to gain more insight into its financial performance.
Amedisys Inc Stock Performance Surges with Positive Outlook for Home Healthcare and Hospice Services
On May 4, 2023, Amedisys Inc saw a surge in its stock performance. The 12 analysts who offer 12-month price forecasts for the company had a median target of $100.00, with a high estimate of $120.00 and a low estimate of $73.00. The current consensus among 14 polled investment analysts is to buy stock in Amedisys Inc. In terms of financial performance, Amedisys Inc reported earnings per share of $1.12 and sales of $568.4 million for the current quarter. The positive outlook for Amedisys Inc can be attributed to several factors, including the demand for home healthcare and hospice services, the company’s strong financial performance, and its strong management team. Investors who are bullish on the healthcare sector should consider adding Amedisys Inc to their portfolio.
Source: beststocks.com
